Vaxil’s immunotherapy products are “universal” in the sense that they can induce an efficient response in the majority of patient populations given their ability to bind multiple MHC (major histocompatibility complexes). This is critical as every individual expresses distinct set of MHC molecules. Unlike many other peptide immunotherapies, Vaxil’s SP domains do not require patients selected based upon their MHC types.
VAXIL – Creating the ideal immunotherapy
Inducing a Broad
Cancer ResistanceLearn More
Immune ResponseLearn More
Cancer Stem CellsLearn More
First Ever SP-Specific
Antibody PlatformLearn More
Vaxil’s Lead Products and Orphan Drug Status
Vaxil believes its immunotherapy platform allows it to target high profile cancer antigens in a uniquely superior manner, all designed to possess the novel advantages described above. Vaxil’s first test of its VaxHit™platform is its ImMucin™ lead immunotherapy product.